Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-08-09
2011-08-09
Sitton, Jehanne S (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07993830
ABSTRACT:
Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4883750 (1989-11-01), Whiteley et al.
patent: 5262311 (1993-11-01), Pardee et al.
patent: 5279721 (1994-01-01), Schmid
patent: 5354855 (1994-10-01), Cech et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5633161 (1997-05-01), Shyjan
patent: 5639656 (1997-06-01), Wright, Jr.
patent: 5658730 (1997-08-01), McGill et al.
patent: 5665547 (1997-09-01), Pardee et al.
patent: 5882864 (1999-03-01), An et al.
patent: 0320308 (1989-06-01), None
patent: 0329822 (1989-08-01), None
patent: 1734134 (2006-12-01), None
patent: 2202328 (1988-09-01), None
patent: WO 87/00880 (1987-02-01), None
patent: WO 88/10315 (1988-12-01), None
patent: WO 89/01025 (1989-02-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 90/07641 (1990-12-01), None
patent: WO 94/10343 (1994-05-01), None
patent: WO 96/22360 (1996-07-01), None
patent: WO 98/04689 (1998-02-01), None
patent: WO 99/37811 (1999-07-01), None
patent: WO 99/64594 (1999-12-01), None
patent: WO 99/64631 (1999-12-01), None
Frohman et al; PNAS, vol. 85, pp. 8998-9002; 1988.
Adam and Wright Jr., “Identification of biomarkers in benign: prostate hyperplasia and prostate carcinoma by differential display,”Proceedings, 86th Annual Meeting American Association for Cancer Research, Mar. 1995.
Alcaraz et al., “Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer,”Cancer Res., 54:3998-4002, 1994.
An et al, “Differential expression of full-length and trucated Her-2
eu oncogene receptor in prostrate cancer assessed using relative quantative RT-PCR,”Molec. Urol., 2:305-309, 1998.
An et al., “Isolation of Genes differentially expressed in prostate cancer cells with metastatic potential by arbitrarily-primed differential analyses (ADA),”Proc. Amer. Assn. Canc. Res., 36:82(491), 1995.
An et al., “Identification of novel gene markers in prostate disease by RNA fingerprinting,”Proc. American Assoc. Cancer Res. Annual Mfg, Abstract No. 1692 37(0):248, 1996.
An et al., “Sensitive, nonradioactive differential display method using chemiluminescent detection,”Biotechniques, 20(3):342, 344, 346, 1996.
Badalament et al., “An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level,”J. Urol., 156:1375-1380, 1996.
Beaudoing et al.,Genome Research, 10:1001-1010, 2001.
Blok et al., “Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR™,”Prostate, 26(4):213-224, 1995.
Bookstein et al., “Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma,”Proc. Natl. Acad. Sci. USA, 87:7762-7766, 1990.
Bookstein et al., “Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene,”Science, 247:712-715, 1990.
Bova et al., “Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer,”Cancer Res., 53:3869-3873, 1993.
Bussemakers et al., “Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis,”Cancer Res., 51:606-611, 1991.
Carter et al., “Allelic loss of chromosomes 16q and 10q in human prostate cancer,”Proc. Natl. Acad. Sci. USA, 87:8751-8755, 1990.
Chen et al., “Androgen-independent human prostate cancer progression: the isolation of novel stage-specific sequences using differential mRNA display,”Proc. Natl. Urol. Assn., 153:267A, 1995.
Deguchi et al., “Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction,”Cancer Research, 53:5350-5354, 1993.
Dong et al,“ KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2, ”Science, 268:884-886, 1995.
Donohue et al., “A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase,”J. Biol. Chem., 269(11):8604-8609, 1994.
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice,”Proc. Nat. Acad. Sci. USA, 81:7529-7533, 1984.
Dumont et al., “Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity,”J. Immunology, 992-1003, 1994.
EMBL. Sequence Data Library, Heidelberg, BRD, XP002019347, Accession No. W67972.
European search report date Feb. 12, 2007.
Garcia-Arenas et al., “The expression of prostatic acid phosphatase in transcriptionally regulated in human prostate carcinoma cells,”Mol. Cell. Endocrin., 111:29-37, 1995.
Gomella et al., “RT-PCR for prostrate specific antigen in the management of prostrate cancer,”J. Urol., 158:326-337, 1997.
Hamdy et al., “Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer,”Brit. J. Urology, 69(4):392-396, 1992.
Isaacs et al., “Molecular biology of prostate cancer,”Seminars in Oncology, 21(5):514-521, 1994.
Isaacs et al., “Wild-typep53suppresses growth of human prostate cancer cells containing mutantp53Alleles,”Cancer Res., 51:4716-4720, 1991.
Kawasaki and Wang, “Detection of gene expression,”In: PCR Technology, Henry A. Erlich (ed.), Stockton Press, 1989.
Liang and Pardee, “Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction,”Science, 257:967-971, 1992.
Liang et al., “Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells,”Cancer Res., 52:6966-6968, 1992.
Lithrup et al, Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.Cancer, Dec. 15;74(12):3146-58, 1994.
Macoska et al., “Fluorescence inSituhybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer,”Cancer Research, 54:3824-3830, 1994.
Mok et al., “Molecular cloning of differentially expressed genes in human epithelial ovarian cancer,”Gynecological Oncology, 52:247-252, 1994.
Morton et al., “Multivariate analysis of the relationship between survival and the microstage of primary melanoma by clark level and breslow thickness,”Cancer, 71(11):3737-3743, 1993.
Morton et al., “Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells,”Cancer Research, 53:3585-3590, 1993.
O'Dowd et al., “Update on the appropriate staging evaluation for newly diagnosed prostate cancer,”J. Urol., 158:687-698, 1997.
Olsson et al., “RT-PCR assays for prostate cancer,”Urol. Clinics of North America ., 24(2):3
An Gang
Veltri Robert
Kilpatrick Townsend and Stockton LLP
Laboratory Corporation of America Holdings
Sitton Jehanne S
LandOfFree
Prostate-specific gene for diagnosis, prognosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate-specific gene for diagnosis, prognosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate-specific gene for diagnosis, prognosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780017